May 19, 2016
National University Corporation Osaka University
Chugai Pharmaceutical Co., Ltd.

Comprehensive Collaboration Agreement
between Osaka University and Chugai~Total of 10 billion yen contribution over 10 years to IFReC~

 Outline
Osaka University and Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced theconclusion of a comprehensive collaboration agreement for advanced research in immunology
between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai.
IFReC was selected for the World Premier International Research Center (WPI) Initiative Program
initiated by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in 2007and launched at Osaka University in October 2007. Headed by Director Shizuo Akira, an eminent
immunologist, IFReC convenes approximately 30 of the world’s top-class principal investigatorsfrom Japan and overseas in the fields of immunology, live imaging and bioinformatics to conduct
innovative immunological research. In March 2011, a new research building was completed on
Osaka University’s Suita Campus providing superior research facilities and an international
environment in which to focus on research. The research conducted by IFReC is of the highest
standard and recognized globally, with papers published in major international journals andprestigious international prizes awarded to its researchers.
Chugai is a leader in the field of biopharmaceuticals and antibody pharmaceuticals in Japan. In
2005 the company succeeded in developing the first domestically-created antibody drug, Actemra.
Currently, Chugai is developing ACE910 (emicizumab) and CIM331 (nemolizumab) using its
proprietary antibody engineering technologies. Going forward, Chugai aims to utilize middle
molecule technologies, which are expected to become another central technology for thedevelopment of new drugs, to focus on the research and development of first-in-class and best-inclass pharmaceuticals.
This comprehensive collaboration will maintain an academic environment that allows researchers
at IFReC to focus on basic research originating from their own ideas, with the aim of contributing
back to society the results of the advanced immunology research. In addition, through thecombination of the global top-class research in immunology at IFReC and the knowledge ofinnovative drug research accumulated by Chugai through its proprietary technologies, theobstacles between basic research and clinical application research will be eliminated. It isexpected that this will lead to the unprecedented discovery of innovative novel drugs in the fieldof immunology.
Chugai will, according to the agreement, provide one billion yen per year for a period of 10 years
in return for access to information on results relating to independent basic research projects atIFReC1) and the right of first refusal for joint research. In addition, a Collaboration Promotion
Laboratory will be set up at IFReC to implement collaboration research toward clinical application.
IFReC and Chugai aim to have five to ten joint research projects in progress constantly. Thecollaboration of two organizations at the top-level of research and technology in the world willseek to achieve significant results that contribute to the benefit of the medical community andhuman health around the world.
【Outline of the comprehensive collaboration agreement】
Period: April 2017 to March 2027
Investment: 1 billion yen per year
Purpose: To benefit the society through further advancement of the basic immunology
research at IFReC as well as contributing to society through the creation of
innovative novel drugs by utilizing the immunology research capabilities at IFReC
in the research and development of innovative pharmaceuticals at Chugai.
Research area: Immune-associated diseases【Collaboration scheme】
1.

IFReC researchers will continue academic basic research without restriction.

2.

Research outcomes of independent research projects1) that IFReC is engaged in will
be regularly disclosed (reported) to Chugai twice per year.

3.

Chugai will select research projects2) for joint research on the basis of the reports.

4.

IFReC researchers will engage in joint research with Chugai.

5.

In and after the final stages of non-clinical research, Chugai may engage in researchdevelopment independently.

【Footnotes】
1) Excluding research projects already under contract with a third party.
2) The number of joint research projects to be engaged in will be decided through discussions between
IFReC and Chugai.

 Comment from Osaka University President Shojiro Nishio
Osaka University promotes collaboration with industry based on the concept “From universityindustry cooperation to university-industry creation (co-creation)” and aims for innovation
toward creation of social value. Chugai has its own drug design development technology andglobal network and is a leader in the field of biopharmaceuticals and antibody pharmaceuticals inJapan. The conclusion of a comprehensive collaborative agreement with Chugai is expected toenhance realization of the innovation the university is aiming for. This collaboration is a newform of university-industry cooperation at Osaka University. The funding for research
activities at the basic research stage will promote basic research for the long-term andstrengthen university-industry cooperation. The success of this collaboration will be an
important foundation for university-industry co-creation at the university and the scheme isexpected to be applied widely.

 Comment from IFReC Director Shizuo AkiraSince its launch in 2007, IFReC has been conducting research toward comprehensive
understanding of the immune system and has achieved internationally-acclaimed exceptional
results in the field of basic immunology. For researchers to continue to advance research basedon their own ideas and in order to advance applied research, we aim to evolve into a research
center that is engaged in medical and clinical immunology. This collaboration will cement
IFReC’s research foundation and maintain IFReC’s level even beyond the end of the support
period for the WPI program in April 2017, thereby facilitating our achievement andcontinuance of the four WPI objectives (advancing leading-edge research, creatinginterdisciplinary domains, establishing international research environments and reformingresearch institutions).

 Comment from Chugai, Chairman & CEO Osamu Nagayama
In recent years, in conjunction with advances in science and technology, academic researchcapabilities are evolving to elucidate in greater detail the mechanisms of the onset of disease at
the molecular level. The pharmaceutical industry is expected to contribute to improving the qualityof medicine by creating innovative pharmaceuticals and at the same time lead Japan’s economy
as a high added-value industry. Drug discovery technology is making immense changes throughthe use of genome research and biotechnology etc., giving rise to the need for a new style ofuniversity-industry cooperation. It is a great honor to have been selected by Osaka University topartner with IFReC in this comprehensive collaboration. Chugai has innovative proprietary
technologies for antibody engineering and middle molecules, which enables drug
discovery of targets that could not be done previously. Through the combination of thesetechnologies and the diverse research results achieved through the global top-classimmunology research at IFReC, we are confident of providing multiple innovative
pharmaceuticals to patients.

 OtherAbout Osaka University
Osaka University was established in 1931 at Nakanoshima, Osaka as the sixth imperial university
and comprised the School of Medicine and the School of Science. In 2007 the university mergedwith the Osaka University of Foreign Studies (established in 1921). The university currently has 11
schools, 16 graduate schools and five affiliated research institutes making it a leading researchoriented comprehensive university in Japan.
Inheriting its ideology and spirit from its origins in Kaitokudo and Tekijuku, Osaka University is
resolved to contribute to the stability and welfare of society, worldwide peace, and harmony
between people and the natural environment. Through the orchestration and co-creation of diverse

knowledge, the university pursues the essence of scholarship at the highest level of education andresearch. The university aims to solve global-scale social problems through the creation of newacademic fields and integrated learning exceeding specialist fields to develop graduates who arecapable of making significant contributions to the creation of a society rich in humanity. The solid
implementation of these aims will lead to our goal of becoming one of the world’s best universities.
As of May 1, 2015, there were 15,535 undergraduate students across Suita, Minoh and Toyonaka
campuses, and 7,886 graduate students. The staff numbered 6,363.
For further details on Osaka University see the website http://www.osaka-u.ac.jp/en/index.html
About the Immunology Frontier Research Center (IFReC)
IFReC was selected for the World Premier International Research Center (WPI) Initiative Program
initiated by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in 2007
and launched at Osaka University on October 1, 2007. Led by internationally-renowned
immunologist Shizuo Akira, the center is a world top-class research institution. The discoverer ofregulatory T cells, Professor Shimon Sakaguchi, and 180 other high-level researchers are leading
the world of immunology at IFReC. IFReC’s goal is to visualize the behavior, activation status, andinteraction of immune cells in vivo through the fusion of immunology, imaging technology andbioinformatics, to understand the immune system comprehensively.
For further details on IFReC see the website http://www.ifrec.osaka-u.ac.jp/en/index.htm
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies withstrengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription
pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an importantmember of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad.
Specifically, Chugai is working to develop innovative products which may satisfy unmet medicalneeds, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new
pharmaceuticals, and laboratories in Ukima are conducting research for technology development
for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged
in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietaryinnovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe
are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2015 of Chugai totalled 498.8 billion yen and the operating income
was 90.7 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english.
About the World Premier International Research Center (WPI) Initiative Program
The World Premier International Research Center (WPI) Initiative was launched in 2007 by theMinistry of Education, Culture, Sports, Science and Technology (MEXT). In the middle ofintensifying competition for securing the world’s finest brains, Japan is facing the increasing needs
to lead the world with its competitive edge in science and technology. In this environment, the WPIprogram aims to build within Japan “globally visible” research centers that boast a very highresearch standard and outstanding research environment, sufficiently attractive to prompt frontline
researchers from around the world. Nine WPI centers have been established, all of which engage
in research activities under strong leadership by center directors to realize four WPI objectives ofadvancing leading-edge research, creating interdisciplinary domains, establishing international
research environments and reforming research institutions.
For further details on WPI see the website
http://www.mext.go.jp/english/research_promotion/1303822.htm

 Inquiries
National University Corporation Osaka University
University-Industry Collaboration Division
Office for University-Industry Collaboration
Tel: +81-6-6879-4200
World Premier International Research Center (WPI) Initiative
International Research Center Support Section
Research Promotion Bureau Basic Research Promotion Division
Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Tel: +81-3-6734-4248
Chugai Pharmaceutical Co., Ltd.
For media
Media Relations Group, Corporate Communications Dept.
Tel: +81-3-3273-0881
E-mail:pr@chugai-pharm.co.jp
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp